|Post IPO Valuation|
CryoLife, Inc. (CryoLife) is a biological medical device company, which has been focused on the development of implantable biological devices, surgical adhesives, and biomaterials for use in cardiac and vascular reconstruction for patients for all ages. The Company preserves and distributes human tissues and develops, manufactures, and commercializes medical devices for cardiac and vascular transplant applications. The human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve (CryoValve SGPV) and the CryoPatch SG pulmonary cardiac patch tissue (CryoPatch SG), both processed using its SynerGraft technology. CryoLifeâ€™s medical devices consist primarily of surgical adhesives, sealants, and hemostats, including BioGlue Surgical Adhesive (BioGlue), BioFoam Surgical Matrix (BioFoam), PerClot and HemoStase. In October of 2010, the Company began distributing PerClot for Starch Medical, Inc. (SMI). In May 2011, it acquired Cardiogenesis Corporation.